U.S. markets closed

Windtree Therapeutics, Inc. (WINT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.2000-0.1200 (-5.17%)
At close: 4:00PM EDT
2.3000 +0.10 (4.55%)
After hours: 07:52PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close2.3200
Open2.3300
Bid2.2300 x 900
Ask2.3000 x 1100
Day's Range2.2000 - 2.3550
52 Week Range1.5800 - 10.0600
Volume662,207
Avg. Volume3,192,782
Market Cap57.766M
Beta (5Y Monthly)-0.10
PE Ratio (TTM)N/A
EPS (TTM)-2.1010
Earnings DateAug 11, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Most Shareholders Will Probably Agree With Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation
    Simply Wall St.

    Most Shareholders Will Probably Agree With Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation

    The performance at Windtree Therapeutics, Inc. ( NASDAQ:WINT ) has been rather lacklustre of late and shareholders may...

  • Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates
    PR Newswire

    Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates

    Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today reported financial results for the first quarter ended March 31, 2021 and provided key business updates.

  • Windtree Therapeutics Announces New Istaroxime Expedited Review Filing of Patent
    PR Newswire

    Windtree Therapeutics Announces New Istaroxime Expedited Review Filing of Patent

    Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has filed a Track One prioritized application with the United States Patent and Trademark Office (USPTO) for a patent stemming from an application it filed previously under the Patent Cooperation Treaty (PCT). Under this USPTO program, the new istaroxime patent is expected to receive examination and final disposition within one year of priority status being granted, rather than the customary three years of examination anticipated by the USPTO for non-prioritized examinations.